MedTrace Logo

The Detection of Small Early Liver Cancer With Natural History Follow up

NCT05534906 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-09-10

No results posted yet for this study

Summary

The SELINA study will recruit 200 patients with cirrhosis and small HCC and 50 patients with HCC but without cirrhosis (most of whom are expected to have FLD). Blood, urine and liver tissue samples (where available) will be collected for laboratory analysis. In a subgroup of patients (N=80, around 64 patients with HCC with liver cirrhosis and around 16 patients with HCC without liver cirrhosis), additional magnetic resonance liver imaging will be performed. The findings of the SELINA study aim to identify biomarkers that can be used to detect liver cancer at the earliest possible time, something we expect will increase the survival rate of HCC.

Conditions

Interventions

OTHER

Blood & Urine Samples

Blood and urine samples will be collected to help identify biomarkers that can be used to detect liver cancer at the earliest possible time

OTHER

Imaging

MRI \& MRE Scans

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Roche Diagnostic Ltd.

    collaborator INDUSTRY

  • OncImmune Ltd

    collaborator UNKNOWN

  • Perspectum

    collaborator INDUSTRY

  • University of Nottingham

    collaborator OTHER

  • Glasgow Caledonian University

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Ellie Barnes · University of Oxford

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2035-06-30
Completion
2035-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05534906 on ClinicalTrials.gov